Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245595 · ClinicalTrials.gov registry record · NA
Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 144
- Enrollment target
NCT01245595: Completed NA study, sponsored by Stanford University.
NCT01245595 is a NA study that has completed, run by Stanford University. The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01245595, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
Study Summary
Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.
Interventions
- DRUG Placebo
- DRUG Aminophylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01245595
The ClinicalTrials.gov registry entry for NCT01245595 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01245595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01245595 about?
NCT01245595 is a clinical study titled "Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery". Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney...
What is the current status of trial NCT01245595?
This trial is currently completed. It is a NA study. The enrollment target is 144 participants. The study started on 2010-11. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01245595?
The interventions under investigation include: Placebo (DRUG), Aminophylline (DRUG).
Who is sponsoring clinical trial NCT01245595?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.